Chen Yiming, Wang Michael, Romaguera Jorge
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Br J Haematol. 2014 Oct;167(1):3-18. doi: 10.1111/bjh.13000. Epub 2014 Jun 28.
Mantle cell lymphoma is a heterogeneous subtype of non-Hodgkin lymphoma. Conventional treatment with immunochemotherapy followed by autologous stem cell transplantation or intensive immunochemotherapy alone has improved outcomes, but the disease remains incurable. Recent advances in basic and translational research have significantly enhanced our understanding of disease pathogenesis and have sparked the development of novel therapies. Novel agents include the proteasome inhibitor bortezomib, the immunomodulatory agent lenalidomide, the phosphatidylinositol-4,5-bisphosphate 3-kinase pathway inhibitor idelalisib and the Bruton tyrosine kinase inhibitor ibrutinib. Preliminary results from clinical trials, especially from studies of ibrutinib, have proven these agents to be effective. In ongoing studies, these agents are being integrated into conventional immunochemotherapy regimens to hopefully improve patient outcomes.
套细胞淋巴瘤是非霍奇金淋巴瘤的一种异质性亚型。采用免疫化疗随后进行自体干细胞移植或单纯强化免疫化疗的传统治疗方法已改善了治疗效果，但该疾病仍然无法治愈。基础研究和转化研究的最新进展显著增进了我们对疾病发病机制的理解，并引发了新型疗法的开发。新型药物包括蛋白酶体抑制剂硼替佐米、免疫调节剂来那度胺、磷脂酰肌醇-4,5-二磷酸3-激酶途径抑制剂艾代拉里斯和布鲁顿酪氨酸激酶抑制剂伊布替尼。临床试验的初步结果，尤其是伊布替尼的研究结果，已证明这些药物是有效的。在正在进行的研究中，这些药物正被纳入传统免疫化疗方案，以期改善患者的治疗效果。
